Cipher Pharmaceuticals Management
Management Kriterienprüfungen 3/4
Cipher Pharmaceuticals CEO ist Craig Mull , ernannt in Jul 2019, hat eine Amtszeit von 6.83 Jahren. besitzt direkt 3.5% der Aktien des Unternehmens, im Wert von CA$15.05M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3 Jahre bzw. 2.9 Jahre.
Wichtige Informationen
Craig Mull
Geschäftsführender
US$966.0k
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | n/a |
| Amtszeit als Geschäftsführer | 6.8yrs |
| Eigentum des Geschäftsführers | 3.5% |
| Durchschnittliche Amtszeit des Managements | 3yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 2.9yrs |
Jüngste Management Updates
Recent updates
Analyseartikel • May 14
Investors Shouldn't Be Too Comfortable With Cipher Pharmaceuticals' (TSE:CPH) Earnings
Cipher Pharmaceuticals Inc. ( TSE:CPH ) announced strong profits, but the stock was stagnant. Our analysis suggests...
Narrativ-Update • May 08
CPH: Higher Cash Returns And Buybacks Will Support Future Upside
Analysts have lifted their price target on Cipher Pharmaceuticals to CA$21 from CA$20, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E. These changes support a slightly higher fair value estimate.Narrativ-Update • Apr 23
CPH: Higher Cash Flow Plans And Buybacks Will Support Future Upside
Analysts have nudged their fair value estimate for Cipher Pharmaceuticals to CA$21 from CA$20, tying the CA$1 price target change to updated assumptions around revenue growth, profit margins and a slightly higher discount rate alongside a lower future P/E. Analyst Commentary Recent research points to a modestly higher fair value for Cipher Pharmaceuticals, with bullish analysts lifting their price target to CA$21 from CA$20.
Narrativ-Update • Apr 09
CPH: Fair Outlook Will Weigh Natroba Expansion And Acquisition Execution
Analysts have nudged their price target on Cipher Pharmaceuticals up to CA$21 from CA$20, citing updated assumptions that keep fair value broadly steady while fine tuning expectations around growth, margins, and P/E levels. Analyst Commentary The latest price target move to CA$21 from CA$20 signals only a modest reset in expectations, rather than a major shift in conviction.Narrativ-Update • Mar 26
CPH: Balanced Outlook Will Weigh New Drug Review And Acquisition Execution
Analysts recently lifted their price target on Cipher Pharmaceuticals to CA$21 from CA$20, reflecting updated assumptions that combine a higher revenue growth outlook with slightly lower profit margin and future P/E expectations. Analyst Commentary The latest price target move to CA$21 suggests that covering analysts are refining their assumptions rather than making a sweeping change in their outlook.Narrativ-Update • Mar 12
CPH: New Drug Review Will Support Future Upside Potential
Analysts are maintaining their CA$18.60 price target on Cipher Pharmaceuticals. This reflects only small adjustments to their revenue growth and future P/E assumptions, rather than a change in their overall view of the stock.Narrativ-Update • Feb 26
CPH: New Drug Review And Strong Margins Will Support Further Upside
Analysts kept their CA$18.60 price target on Cipher Pharmaceuticals unchanged, citing only small tweaks to their revenue growth, profit margin and future P/E assumptions that did not materially shift their view of the stock’s value. What's in the News Health Canada accepted Cipher Pharmaceuticals' new drug submission for Natroba (Spinosad) for the treatment of head lice and scabies, moving the product into the formal review process (Key Developments).Narrativ-Update • Feb 11
CPH: Higher Margins And New Submission Will Support Future Upside
Analysts have trimmed their price target on Cipher Pharmaceuticals to reflect a more muted revenue growth outlook of 4.30% and a slightly higher discount rate of 6.25%, while still acknowledging a stronger projected profit margin of 39.46% and a broadly similar future P/E of 17.63. What's in the News Health Canada accepted Cipher Pharmaceuticals' new drug submission for Natroba (Spinosad), targeting head lice and scabies in the Canadian market (Key Developments).Narrativ-Update • Jan 26
CPH: Share Repurchases Will Drive Future Earnings Power And Upside Potential
Analysts have modestly adjusted their price target for Cipher Pharmaceuticals to reflect slightly updated assumptions around revenue growth of 10.48%, profit margin of 32.39%, and a future P/E of 17.81x. The overall fair value estimate remains at $18.60.Narrativ-Update • Jan 11
CPH: Share Repurchases Will Support Stronger Future Earnings Profile
Analysts have trimmed their price target on Cipher Pharmaceuticals by aligning slightly lower revenue growth and profit margin assumptions with a modestly higher future P/E. This keeps fair value around $18.60 and reflects a more measured outlook on the company’s earnings profile.Narrativ-Update • Dec 27
CPH: Share Repurchases And Rising Margins Will Support Stronger Future Earnings
Cipher Pharmaceuticals' analyst price target has been raised from 14.50 dollars to 18.60 dollars, as analysts cite slightly stronger expected revenue growth, modestly higher profit margins, and a richer future earnings multiple as justification for the upward revision. What's in the News Cipher Pharmaceuticals completed the latest tranche of its share repurchase program between July 1, 2025 and September 30, 2025, buying back 141,700 shares, or 0.56 percent of its float, for CAD 2.18 million (Key Developments) Under the buyback announced on May 1, 2025, the company has now repurchased a total of 371,978 shares, representing 1.46 percent of shares outstanding, for aggregate consideration of CAD 5.12 million (Key Developments) Valuation Changes The consensus analyst price target has risen significantly from 14.50 dollars to 18.60 dollars, reflecting a materially higher fair value assessment.Narrativ-Update • Dec 12
CPH: Share Buybacks Will Support Earnings And Maintain A Balanced Outlook
Analysts have nudged their price target on Cipher Pharmaceuticals higher, from 14.00 dollars to 14.50 dollars, citing stronger expected revenue growth, improved profit margins, and a more attractive forward earnings multiple despite a slightly higher discount rate. What's in the News Cipher Pharmaceuticals repurchased 141,700 shares between July 1 and September 30, 2025, totaling CAD 2.18 million and representing 0.56% of outstanding shares (company buyback update).Analyseartikel • Nov 09
Cipher Pharmaceuticals Inc. (TSE:CPH) Analysts Are Pretty Bullish On The Stock After Recent Results
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders are probably feeling a little disappointed, since its shares fell...Analyseartikel • Oct 10
These 4 Measures Indicate That Cipher Pharmaceuticals (TSE:CPH) Is Using Debt Extensively
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Narrativ-Update • Sep 05
Expansion Into Canada Will Shape Global Dermatology Success
Cipher Pharmaceuticals' future P/E has risen sharply, indicating increased valuation relative to earnings, while the net profit margin is stable, resulting in no change to the consensus analyst price target at CA$17.90. What's in the News Cipher Pharmaceuticals is actively seeking accretive acquisitions and in-licensing opportunities, with a strategic focus on complementary U.S.-based assets and companies.Analyseartikel • Aug 29
Cipher Pharmaceuticals Inc.'s (TSE:CPH) Shares Climb 27% But Its Business Is Yet to Catch Up
The Cipher Pharmaceuticals Inc. ( TSE:CPH ) share price has done very well over the last month, posting an excellent...Analyseartikel • May 16
We Think That There Are More Issues For Cipher Pharmaceuticals (TSE:CPH) Than Just Sluggish Earnings
Investors weren't pleased with the recent soft earnings report from Cipher Pharmaceuticals Inc. ( TSE:CPH ). Our...Analyseartikel • May 09
Cipher Pharmaceuticals Inc. (TSE:CPH) Stocks Shoot Up 29% But Its P/E Still Looks Reasonable
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shares have had a really impressive month, gaining 29% after a shaky period...Analyseartikel • Apr 28
Is Cipher Pharmaceuticals (TSE:CPH) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Neues Narrativ • Feb 23
Acquisition Of Natroba And Pipeline Products Will Strengthen Future Market Presence
Strategic acquisitions and transitioning to an in-house sales team are aimed at reducing costs and boosting revenue and earnings for Cipher Pharmaceuticals.Analyseartikel • Dec 13
We Think Cipher Pharmaceuticals (TSE:CPH) Is Taking Some Risk With Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Nov 14
Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think
Cipher Pharmaceuticals Inc.'s ( TSE:CPH ) earnings announcement last week contained some soft numbers, disappointing...Analyseartikel • Nov 12
With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders won't be pleased to see that the share price has had a very rough...Analyseartikel • Nov 09
Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders are probably feeling a little disappointed, since its shares fell...Analyseartikel • Mar 23
There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shares have continued their recent momentum with a 26% gain in the last month...Analyseartikel • Mar 22
Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)
The market rallied behind Cipher Pharmaceuticals Inc.'s ( TSE:CPH ) stock, leading do a rise in the share price after...Geschäftsführer
Craig Mull
6.8yrs
Amtszeit
US$966,027
Vergütung
Mr. Craig J. Mull has been Chairman of the Board of Directors at Cipher Pharmaceuticals Inc. since June 11, 2019 and serves as its Interim Chief Executive Officer since July 29, 2019, served as its Preside...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Interim CEO & Chairman of the Board | 6.8yrs | US$966.03k | 3.5% CA$ 15.0m | |
| President | 1.8yrs | US$890.02k | 0.036% CA$ 153.8k | |
| Chief Financial Officer | 1.8yrs | US$370.38k | keine Daten | |
| Director of Sales & Marketing | 4.3yrs | keine Daten | keine Daten | |
| Corporate Controller | no data | keine Daten | keine Daten |
3.0yrs
Durchschnittliche Betriebszugehörigkeit
Erfahrenes Management: CPHDas Führungsteam des Unternehmens gilt als erfahren (3 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Interim CEO & Chairman of the Board | 7.2yrs | US$966.03k | 3.5% CA$ 15.0m | |
| Independent Director | 2.9yrs | US$38.26k | 0.0053% CA$ 22.6k | |
| Independent Director | 2.9yrs | US$33.04k | 0.0053% CA$ 22.6k |
2.9yrs
Durchschnittliche Betriebszugehörigkeit
Erfahrener Vorstand: CPHDie Vorstandsmitglieder gelten nicht als erfahren ( 2.9 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/21 01:39 |
| Aktienkurs zum Tagesende | 2026/05/21 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Cipher Pharmaceuticals Inc. wird von 8 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| David Novak | ATB Cormark Historical (Cormark Securities) |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Prakash Gowd | CIBC Capital Markets |